Rana Hejal, MD
- Medical Director, Respiratory Therapy, University Hospitals
- Medical Director, MICU, UH Cleveland Medical Center
- Clinical Associate Professor, CWRU School of Medicine
- Specialty: Pulmonary and Critical Care Medicine, Pulmonary Disease
- Call: 216-844-8500
Biography: Rana Hejal, MD
Expertise
Certifications & Memberships
- Critical Care Medicine - American Board of Internal Medicine
- Pulmonary Disease - American Board of Internal Medicine
Education
Research Fellowship | Pulmonary Disease
Pulmonary Disease - University Hospitals Of Cleveland (1994 - 1995)
Fellowship | Pulmonary Disease
Pulmonary Disease - University Hospitals Of Cleveland (1991 - 1994)
Residency | Internal Medicine
Internal Medicine - Metrohealth Medical Center (1989 - 1991)
Internship | Internal Medicine
Internal Medicine - Metrohealth Medical Center (1988 - 1989)
Medical Education
American University Of Beirut (1988)
Undergraduate
American University Of Beirut (1984)
About
Dr. Rana Hejal graduated from American University of Beirut in 1988. She completed her residency and fellowship in pulmonary and critical care medicine at University Hospitals Case Medical Center/Case Western Reserve University in Cleveland.
Dr. Hejal’s career encompasses a wide range of clinical, educational and leadership roles. She has won several teaching awards, including the prestigious Master Clinician in Internal Medicine.
Dr. Hejal is director of the medical intensive care unit at University Hospitals Cleveland Medical Center, which, under her leadership, is a consistent Beacon Award winner.
Dr. Hejal’s area of expertise in pulmonary medicine focuses on advanced lung disease, including interstitial lung disease (ILD) and sarcoidosis. She focuses on a multidisciplinary approach to treating ILD patients and is actively involved in ILD clinical research.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Rana Hejal did not disclose any Outside Relationships with Industry.